RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oryzon Genomics Stock

Oryzon Genomics ROA 2024

Oryzon Genomics ROA

-0.03

Ticker

ORY.MC

ISIN

ES0167733015

WKN

A2ACV2

In 2024, Oryzon Genomics's return on assets (ROA) was -0.03, a -23.13% increase from the -0.04 ROA in the previous year.

Oryzon Genomics Aktienanalyse

What does Oryzon Genomics do?

The company Oryzon Genomics SA is a biopharmaceutical company that was founded in 2000 in Barcelona, Spain. Since then, the company has gained a growing reputation for the development of innovative therapeutic approaches for serious diseases. Oryzon works on the development of epigenetic products that focus on molecular docking sites in the cell to modulate approved proteins and fragments. They use a unique technology called ORY-1001 to promote tumor apoptosis. The technology involves the use of epigenetic modulators to develop therapeutic approaches for certain types of cancer such as CLL and leukemia. Oryzon operates various divisions such as Research and Development, Intellectual Property, and Product Development. Within Research and Development, they work on the research and development of new technologies and products. They also have a portfolio of patented and potential patent applications in the field of epigenetics and products for the treatment of various types of cancer, neurodegenerative diseases such as Alzheimer's, and schizophrenia. The Intellectual Property division is responsible for all of Oryzon's patent rights. They review all of Oryzon's patents to ensure they meet the highest standards of patent law. The Product Development department helps the company in transferring newly developed products into effective and approved drugs. They also assist in the approval process by health authorities, particularly in the field of clinical trials. At the beginning of 2020, Oryzon announced that they will start a Phase 2 clinical trial for their product line ORY-2001 for the treatment of Alzheimer's patients. ORY-2001 is a selective histone deacetylase (HDAC) inhibitor aimed at slowing down the pathological process of Alzheimer's and other neurodegenerative diseases. This technology has the potential to improve the lives of millions of patients worldwide. In 2017, the company acquired WNT research from Inthera Bioscience SA, a biotechnology company focused on cancer treatment. The acquisition expanded Oryzon Genomics' portfolio to develop new innovative cancer therapies. The field of epigenetics is considered a rising and promising area in the medical industry. Oryzon Genomics has successfully positioned itself as a leading company in this field and continues to work on developing innovative solutions for the treatment of life-threatening diseases. The company remains a company to watch in the biopharmaceutical industry in the coming years. Oryzon Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Oryzon Genomics's Return on Assets (ROA)

Oryzon Genomics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Oryzon Genomics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Oryzon Genomics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Oryzon Genomics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Oryzon Genomics stock

What is the Return on Assets (ROA) of Oryzon Genomics this year?

The Return on Assets (ROA) of Oryzon Genomics is -0.03 undefined this year.

What was the ROA of Oryzon Genomics compared to the previous year?

The ROA of Oryzon Genomics has increased by -23.13% compared to the previous year.

What consequences do high ROA have for investors of Oryzon Genomics?

A high ROA is advantageous for investors of Oryzon Genomics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Oryzon Genomics?

A low ROA can be unfavorable for investors of Oryzon Genomics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Oryzon Genomics affect the company?

An increase in ROA of Oryzon Genomics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Oryzon Genomics impact the company?

A reduction in the ROA of Oryzon Genomics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Oryzon Genomics?

Some factors that can influence the ROA of Oryzon Genomics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Oryzon Genomics important for investors?

The ROA of Oryzon Genomics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Oryzon Genomics take to improve ROA?

To improve ROA, Oryzon Genomics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Oryzon Genomics pay?

Over the past 12 months, Oryzon Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oryzon Genomics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Oryzon Genomics?

The current dividend yield of Oryzon Genomics is .

When does Oryzon Genomics pay dividends?

Oryzon Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oryzon Genomics?

Oryzon Genomics paid dividends every year for the past 0 years.

What is the dividend of Oryzon Genomics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oryzon Genomics located?

Oryzon Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oryzon Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oryzon Genomics from 10/15/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/15/2024.

When did Oryzon Genomics pay the last dividend?

The last dividend was paid out on 10/15/2024.

What was the dividend of Oryzon Genomics in the year 2023?

In the year 2023, Oryzon Genomics distributed 0 EUR as dividends.

In which currency does Oryzon Genomics pay out the dividend?

The dividends of Oryzon Genomics are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oryzon Genomics

Our stock analysis for Oryzon Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oryzon Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.